Ginkgo Bioworks Holdings, Inc.DNAEarnings & Financial Report
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...
DNA Q4 FY2025 Key Financial Metrics
Revenue
$33.4M
Gross Profit
N/A
Operating Profit
$-70.8M
Net Profit
N/A
Gross Margin
N/A
Operating Margin
-211.9%
Net Margin
N/A
YoY Growth
-23.8%
EPS
$-1.41
Ginkgo Bioworks Holdings, Inc. Q4 FY2025 Financial Summary
Ginkgo Bioworks Holdings, Inc. reported revenue of $33.4M (down 23.8% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin).
Key Financial Metrics
| Total Revenue | $33.4M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | -211.9% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Ginkgo Bioworks Holdings, Inc. Q4 FY2025 revenue of $33.4M breaks down across 2 segments, led by Cell Engineering Segment at $26.0M (77.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Cell Engineering Segment | $26.0M | 77.9% |
| Other | $7.4M | 22.1% |
Ginkgo Bioworks Holdings, Inc. Revenue by Segment — Quarterly Trend
Ginkgo Bioworks Holdings, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Cell Engineering Segment and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Cell Engineering Segment | $26.0M | $29.4M | — | — |
| Other | $7.4M | — | — | — |
Ginkgo Bioworks Holdings, Inc. Annual Revenue by Year
Ginkgo Bioworks Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $170.2M).
Ginkgo Bioworks Holdings, Inc. Quarterly Revenue & Net Profit History
Ginkgo Bioworks Holdings, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $33.4M | -23.8% | N/A | N/A |
| Q3 FY2025 | $38.8M | -56.4% | $-80.8M | -207.9% |
| Q2 FY2025 | $49.6M | -11.7% | $-60.3M | -121.6% |
| Q1 FY2025 | $48.3M | +27.3% | $-91.0M | -188.2% |
| Q4 FY2024 | $43.8M | +26.2% | N/A | N/A |
| Q3 FY2024 | $89.0M | +60.6% | $-56.4M | -63.3% |
| Q2 FY2024 | $56.2M | -30.2% | $-217.2M | -386.4% |
| Q1 FY2024 | $37.9M | -53.0% | $-165.9M | -437.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37.9M | $56.2M | $89.0M | $43.8M | $48.3M | $49.6M | $38.8M | $33.4M |
| YoY Growth | -53.0% | -30.2% | 60.6% | 26.2% | 27.3% | -11.7% | -56.4% | -23.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.58B | $1.63B | $1.48B | $1.38B | $1.29B | $1.23B | $1.19B | $1.12B |
| Liabilities | $594.5M | $792.2M | $682.9M | $661.4M | $646.0M | $618.1M | $629.4M | $611.1M |
| Equity | $987.3M | $833.1M | $797.9M | $716.1M | $647.4M | $613.0M | $559.8M | $508.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-89.3M | $-84.4M | $-103.5M | $-42.4M | $-51.5M | $-40.3M | $-31.6M | $-47.7M |